PMC:7784830 / 7139-7343 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"133","span":{"begin":27,"end":46},"obj":"Chemical"},{"id":"134","span":{"begin":127,"end":138},"obj":"Chemical"}],"attributes":[{"id":"A133","pred":"tao:has_database_id","subj":"133","obj":"MESH:C558899"},{"id":"A134","pred":"tao:has_database_id","subj":"134","obj":"MESH:C462182"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"sing drug when compared to lopinavir/ritonavir. In India, Glenmark Pharmaceuticals has initiated phase III clinical trials for favipiravir and is expected to complete the trials by end of August 2020 [42]"}